Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024
Lumos Pharma (NASDAQ:LUMO) announced that two abstracts featuring analyses from their Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting (ESPE 2024). The presentations, scheduled for November 17-18, 2024 in Liverpool, UK, will focus on LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD). The abstracts will cover growth responses and hormone secretion patterns in PGHD patients over 12-24 months of treatment.
Lumos Pharma (NASDAQ:LUMO) ha annunciato che due abstract contenenti analisi dei loro trial clinici di Fase 2 OraGrowtH210 e OraGrowtH212 sono stati accettati per presentazione orale alla 62ª Riunione Annuale della Società Europea di Endocrinologia Pediatrica (ESPE 2024). Le presentazioni, programmate per il 17-18 novembre 2024 a Liverpool, Regno Unito, si concentreranno su LUM-201, un trattamento orale per la Deficienza di Ormone della Crescita Pediatrica (PGHD). Gli abstract copriranno le risposte alla crescita e i modelli di secrezione ormonale nei pazienti affetti da PGHD durante 12-24 mesi di trattamento.
Lumos Pharma (NASDAQ:LUMO) anunció que dos resúmenes con análisis de sus ensayos clínicos de Fase 2 OraGrowtH210 y OraGrowtH212 han sido aceptados para presentación oral en la 62ª Reunión Anual de la Sociedad Europea de Endocrinología Pediátrica (ESPE 2024). Las presentaciones, programadas para el 17-18 de noviembre de 2024 en Liverpool, Reino Unido, se centrarán en LUM-201, un tratamiento oral para la Deficiencia de Hormona del Crecimiento Pediátrica (PGHD). Los resúmenes abordarán las respuestas de crecimiento y los patrones de secreción hormonal en pacientes con PGHD durante 12-24 meses de tratamiento.
루모스 파르마 (NASDAQ:LUMO)는 두 개의 초록이 그들의 2상 임상시험 OraGrowtH210 및 OraGrowtH212에 대한 분석을 포함하여 62회 연례 유럽 소아내분비학회(ESPE 2024)에서 구두 발표를 위해 채택되었다고 발표했다. 발표는 2024년 11월 17-18일 영국 리버풀에서 예정되어 있으며, 소아 성장 호르몬 결핍증(PGHD)을 위한 경구 치료제인 LUM-201에 초점을 맞출 예정이다. 초록은 PGHD 환자의 12-24개월 치료 동안의 성장 반응 및 호르몬 분비 패턴을 다룰 것이다.
Lumos Pharma (NASDAQ:LUMO) a annoncé que deux résumés contenant des analyses de ses essais cliniques de phase 2 OraGrowtH210 et OraGrowtH212 ont été acceptés pour présentation orale lors de la 62e Réunion Annuelle de la Société Européenne d'Endocrinologie Pédiatrique (ESPE 2024). Les présentations, prévues pour le 17 et 18 novembre 2024 à Liverpool, au Royaume-Uni, se concentreront sur LUM-201, un traitement oral pour la Déficience en Hormone de Croissance Pédiatrique (PGHD). Les résumés aborderont les réponses de croissance et les motifs de sécrétion hormonale chez les patients atteints de PGHD pendant 12-24 mois de traitement.
Lumos Pharma (NASDAQ:LUMO) gab bekannt, dass zwei Abstracts mit Analysen aus ihren Phase-2-Studien OraGrowtH210 und OraGrowtH212 zur mündlichen Präsentation auf dem 62. Jahreskongress der Europäischen Gesellschaft für Pädiatrische Endokrinologie (ESPE 2024) akzeptiert wurden. Die Präsentationen, die für den 17. und 18. November 2024 in Liverpool, Großbritannien, geplant sind, konzentrieren sich auf LUM-201, eine orale Behandlung für die pädiatrische Wachstums-Hormon-Defizienz (PGHD). Die Abstracts werden Wachstumsreaktionen und Hormonsekretionsmuster bei PGHD-Patienten über einen Zeitraum von 12-24 Monaten der Behandlung abdecken.
- None.
- None.
AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company’s Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK.
Two abstracts on data from the OraGrowtH Trials evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on Sunday, November 17th, by Elżbieta Petriczko, MD, PhD, Pomeranian Medical University, Szczecin, Poland, and on Monday, November 18th, by Peter E. Clayton, MD, University of Manchester, Manchester, UK, respectively.
LUM-201 Oral Abstract Presentations:
Sunday, November 17th – Session: Free Communications 7: GH and IGFs – 10:50AM Local Time
- FC7.6 Abstract entitled, Growth, IGF-1 and IGFBP-3 Responses to Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Pediatric Growth Hormone Deficiency (PGHD) Over 12 to 24 Months on Treatment (Elżbieta Petriczko, MD, PhD, et al)
Monday, November 18th – Session: Free Communications 15: Late Breaking – 9:40AM Local Time
- FC15.2 Abstract entitled, Amount and Pattern of Pulsatile GH Secretion Induced by the Oral Growth Hormone Secretagogue LUM-201 Is Related to Growth and IGF-1 Responses in Moderate Pediatric Growth Hormone Deficiency (PGHD) (Peter E. Clayton, MD, et al)
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
FAQ
When will Lumos Pharma (LUMO) present their OraGrowtH clinical trial data at ESPE 2024?
What are the Phase 2 clinical trials of Lumos Pharma (LUMO) evaluating?
Who will present the Lumos Pharma (LUMO) clinical trial data at ESPE 2024?
